Organization (Industry)
BIOCRYST PHARMACEUTICALS INC
ClinicalTrials.gov lists BIOCRYST PHARMACEUTICALS INC as lead sponsor of 61 trials, counting the companies grouped under it. BIOCRYST PHARMACEUTICALS INC itself has 35 active development programs and 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo BioCryst Pharmaceuticals, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers BIOCRYST PHARMACEUTICALS INC and 1 company grouped under it: 61 lead-sponsored trials (54 its own, 7 in the grouped companies) and 2 legal-entity registrations (2 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Astria Therapeutics, Inc. | 7 | 0 |
Disease areas (84)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Angioedema | 17 |
| Angioedemas, Hereditary | 17 |
| Primary Immunodeficiency Diseases | 17 |
| Influenza, Human | 11 |
| Lymphoma | 7 |
Showing 5 of 84 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 3 |
| 2018 | 4 |
| 2017 | 3 |
| 2016 | 2 |
| 2015 | 4 |
Showing 10 of 22 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (35)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Berotralstat | Angioedemas, Hereditary | Phase 3 | 3 |
| Berotralstat | Angioedema | Phase 3 | 3 |
| Berotralstat | Primary Immunodeficiency Diseases | Phase 3 | 3 |
| BCX4161 | Angioedemas, Hereditary | Phase 3 | 5 |
| BCX4161 | Primary Immunodeficiency Diseases | Phase 3 | 5 |
Showing 5 of 35 active programs.
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Peramivir | 6 |
| Berotralstat | 3 |
| Oseltamivir | 2 |
| BCX7353 | 6 |
| Forodesine | 8 |
Showing 5 of 10 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=18) | 35% on time (n=17) |
Journals published in (18)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | 3 |
| Antiviral therapy | 2 |
| The World Allergy Organization journal | 2 |
| Allergy | 1 |
| Allergy and asthma proceedings | 1 |
Showing 5 of 18 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 88 | 25 | 2025-12-23 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | not reported | 263,861,000 | 166,126,000 |
| 2024 | not reported | -88,881,000 | 174,638,000 |
| 2023 | not reported | -226,539,000 | 216,566,000 |
| 2022 | not reported | -247,116,000 | 253,297,000 |
| 2021 | not reported | -184,062,000 | 208,808,000 |
| 2020 | not reported | -182,814,000 | 122,964,000 |
| 2019 | not reported | -108,897,000 | 107,068,000 |
| 2018 | not reported | -101,252,000 | 84,888,000 |
| 2017 | 25,186,000 | -65,782,000 | 66,962,000 |
| 2016 | 26,353,000 | -55,144,000 | 61,008,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (40)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-04 | Royalty / licensing | 70,000,000 | Sec extracted |
| 2026-01-23 | Debt financing | 400,000,000 | Sec extracted |
| 2025-12-18 | Other financing | not disclosed | Edgar offerings |
| 2025-10-14 | Debt financing | not disclosed | Sec extracted |
| 2025-10-14 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 40 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 3 |
| Department of Health and Human Services | Co sponsors trial with | 1 |
Latest dated events (189)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-04 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-23 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-18 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-12 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
Showing 5 of 189 events.
Biomarker capability evidence (94)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP4A | Trial sponsor | Named in trial inclusion criteria |
| ATP4A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 94 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.